Abstract
The principle of this method was to screen the pharmacological activity of ten prepared polyphyto formulations by using highthroughput screening method for their antihyperlipidemic activity. The study was performed in three stages using single animal, two animals and three animals in a group. The data produced with single animal is compared with the average data shown by two and three experimental animals and further with six animals (one way ANOVA) for the statistical significance and was duly reported. R2 value was determined by Least squares linear regression analysis to interpret as the proportion of the variance in the dependent variable that is predictable from the independent variable. Test formulations were given at 50mg/kg, body weight through p.o. route daily for 14 days in experimental animals induced with hyperlipidemia by injecting Triton X-100 at 100 mg/kg BW i/p and observed for 48 hrs for the development of hyperlipidemia. Two best formulations namely PHF-21 and PHF-26 were selected by highthroughput screening and results repeated in six animals in a group were found to be statically similar.
Keywords: Antihyperlipidemic, ANOVA, highthroughput, linear regression, Triton X-100.
Graphical Abstract
Current Bioactive Compounds
Title:Preliminary Pharmacological Screening of Anti-Hyperlipidemic Polyphyto Combination by Novelistic Highthroughput Screening Method
Volume: 12 Issue: 2
Author(s): Asha Bisht, Satheesh N.V. Madhav and Kumud Upadhyaya
Affiliation:
Keywords: Antihyperlipidemic, ANOVA, highthroughput, linear regression, Triton X-100.
Abstract: The principle of this method was to screen the pharmacological activity of ten prepared polyphyto formulations by using highthroughput screening method for their antihyperlipidemic activity. The study was performed in three stages using single animal, two animals and three animals in a group. The data produced with single animal is compared with the average data shown by two and three experimental animals and further with six animals (one way ANOVA) for the statistical significance and was duly reported. R2 value was determined by Least squares linear regression analysis to interpret as the proportion of the variance in the dependent variable that is predictable from the independent variable. Test formulations were given at 50mg/kg, body weight through p.o. route daily for 14 days in experimental animals induced with hyperlipidemia by injecting Triton X-100 at 100 mg/kg BW i/p and observed for 48 hrs for the development of hyperlipidemia. Two best formulations namely PHF-21 and PHF-26 were selected by highthroughput screening and results repeated in six animals in a group were found to be statically similar.
Export Options
About this article
Cite this article as:
Bisht Asha, N.V. Madhav Satheesh and Upadhyaya Kumud, Preliminary Pharmacological Screening of Anti-Hyperlipidemic Polyphyto Combination by Novelistic Highthroughput Screening Method, Current Bioactive Compounds 2016; 12 (2) . https://dx.doi.org/10.2174/157340721202160504221515
DOI https://dx.doi.org/10.2174/157340721202160504221515 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Photosensitization of Biomolecules by Phenothiazine Derivatives
Current Drug Targets COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods
Anti-Cancer Agents in Medicinal Chemistry The Impact of Small Heat Shock Proteins (HspBs) in Alzheimer’s and Other Neurological Diseases
Current Pharmaceutical Design Adenosine and Related Drugs in Brain Diseases: Present and Future in Clinical Trials
Current Topics in Medicinal Chemistry Drug Repositioning for Treatment of Movement Disorders: From Serendipity to Rational Discovery Strategies
Current Topics in Medicinal Chemistry Acute Severe Colitis: Infliximab and/or Cyclosporine?
Current Drug Targets Microdialysis in Neurointensive Care
Current Pharmaceutical Design From Stem Cells to Dopamine Neurons: Developmental Biology Meets Neurodegeneration
CNS & Neurological Disorders - Drug Targets Drugs From the Sea: Conotoxins as Drug Leads for Neuropathic Pain and Other Neurological Conditions
Mini-Reviews in Medicinal Chemistry Dementia Etiologies and Remedies in Traditional Persian Medicine; A Review of Medicinal Plants and Phytochemistry
Current Drug Metabolism LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function
Current Protein & Peptide Science Regulation of Dopamine Signaling in the Striatum by Phosphodiesterase Inhibitors: Novel Therapeutics to Treat Neurological and Psychiatric Disorders
Central Nervous System Agents in Medicinal Chemistry Gangliosides Potentially Inhibit Extracellular Nucleotide Metabolism
Current Medicinal Chemistry Risperidone Long-Acting Injection in the Treatment of First Episode Schizophrenia
Current Psychopharmacology Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety Hyperglycemia, Hypoglycemia and Dementia: Role of Mitochondria and Uncoupling Proteins
Current Molecular Medicine Cellular, Molecular and Non-Pharmacological Therapeutic Advances for the Treatment of Parkinson's Disease: Separating Hope from Hype
Current Gene Therapy Neuroprotection of Coenzyme Q10 in Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease
Current Neuropharmacology Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders
Current Pharmaceutical Design